Supplementary Material

Real-world treatment patterns after CD19-directed CAR T-cell therapy among patients with diffuse large B-cell lymphoma

Jessica J. Jalbert\textsuperscript{a}, Ning Wu\textsuperscript{a}, Chieh-I Chen\textsuperscript{a}, Srikanth Ambati\textsuperscript{a}, Wenzhen Ge\textsuperscript{a}, Jon E. Arnason\textsuperscript{b}

\textsuperscript{a}Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; \textsuperscript{b}Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Corresponding author: Jessica J. Jalbert, jessica.jalbert@regeneron.com
Table S1. Systemic treatments administered within 6 months pre-index

| Category       | Systemic Treatment              | Total, n (%) |
|----------------|---------------------------------|--------------|
|                |                                 | N = 129      |
| Chemotherapy   | Gemcitabine                     | 24 (18.6)    |
|                | Doxorubicin                     | 21 (16.3)    |
|                | Vincristine                     | 21 (16.3)    |
|                | Etoposide                       | 19 (14.7)    |
|                | Cisplatin                       | 11 (8.5)     |
|                | Oxaliplatin                     | 11 (8.5)     |
|                | Carboplatin                     | 10 (7.8)     |
|                | Methotrexate                    | 10 (7.8)     |
|                | Ifosfamide                      | 9 (7.0)      |
|                | Cytarabine                      | 7 (5.4)      |
|                | Bendamustine                    | 6 (4.7)      |
|                | Procarbazine                    | 2 (1.6)      |
|                | Vinorelbine                     | 1 (0.8)      |
| Immunotherapy  | Rituximab                       | 59 (45.7)    |
|                | Lenalidomide                    | 11 (8.5)     |
|                | Brentuximab                     | 5 (3.9)      |
|                | Obinutuzumab                    | 2 (1.6)      |
|                | Pembrolizumab                   | 2 (1.6)      |
| Targeted therapy| Ibrutinib                      | 9 (7.0)      |
|                | Venetoclax                      | 4 (3.1)      |
|                | Acalabrutinib                   | 1 (0.8)      |
|                | Copanlisib                      | 1 (0.8)      |
| Transplant     | Hematopoietic stem cell transplant | 7 (5.4)    |
| Pt | Follow-up, days | First line of therapy | Days from CAR T to first<sup>a</sup> | Second line of therapy | Days from first to second<sup>a</sup> |
|----|----------------|-----------------------|-----------------------------------|------------------------|----------------------------------|
| 1  | 120            | Ibrutinib             | 9                                 |                        |                                  |
| 2  | 77             | Obinutuzumab          | 11                                |                        |                                  |
| 3  | 101            | Transplant<sup>b</sup>| 17                                |                        |                                  |
| 4  | 267            | Ibrutinib             | 17                                |                        |                                  |
| 5  | 86             | Ibrutinib             | 24                                |                        |                                  |
| 6  | 85             | Ibrutinib, Rituximab  | 25                                |                        |                                  |
| 7  | 91             | Ibrutinib, Lenalidomide, Obinutuzumab, Venetoclax | 44 |                        |                                  |
| 8  | 276            | Etoposide             | 53                                |                        |                                  |
| 9  | 128            | Gemcitabine, Oxaliplatin, Rituximab | 56 |                        |                                  |
| 10 | 134            | Brentuximab           | 58                                |                        |                                  |
| 11 | 260            | Lenalidomide, Ibrutinib, Venetoclax | 73 | Pembrolizumab | 85 |
| 12 | 157            | Lenalidomide, Ibrutinib, Venetoclax | 75 |                        |                                  |
| 13 | 642            | Cisplatin, Gemcitabine, Pembrolizumab, Rituximab | 82 | Transplant<sup>b</sup> | 122 |
| 14 | 240            | Cytarabine, Rituximab | 91 |                        |                                  |
| 15 | 387            | Lenalidomide          | 94                                |                        |                                  |
| 16 | 154            | Bendamustine, Rituximab | 99 |                        |                                  |
| 17 | 167            | Transplant<sup>b</sup> | 100 |                        |                                  |
| 18 | 201            | Bendamustine, Brentuximab, Gemcitabine, Oxaliplatin, Rituximab | 100 |                        |                                  |
| 19 | 358            | Lenalidomide, Rituximab | 113 | Bendamustine, rituximab, transplant<sup>b</sup> | 118 |
| 20 | 567            | Transplant<sup>b</sup>, Lenalidomide, Rituximab | 114 | Gemcitabine, oxaliplatin, rituximab | 435 |
| Pt | Follow-up, days | First line of therapy | Days from CAR T to first \(^a\) | Second line of therapy | Days from first to second \(^a\) |
|----|----------------|-----------------------|-------------------------------|------------------------|--------------------------------|
| 21 | 216            | Lenalidomide          | 114                           | -                      |                                |
| 22 | 141            | Bendamustine          | 116                           | -                      |                                |
| 23 | 194            | Pembrolizumab         | 120                           | -                      |                                |
| 24 | 140            | Rituximab             | 120                           | -                      |                                |
| 25 | 398            | Ibrutinib             | 123                           | Cyclophosphamide       | 100                            |
|    |                |                       |                               | doxorubicin             |                                |
|    |                |                       |                               | lenalidomide            |                                |
|    |                |                       |                               | rituximab               |                                |
| 26 | 193            | Pembrolizumab         | 124                           | -                      |                                |
| 27 | 499            | Pembrolizumab         | 124                           | -                      |                                |
| 28 | 428            | Bendamustine          | 126                           | -                      |                                |
| 29 | 347            | Pembrolizumab         | 154                           | -                      |                                |
| 30 | 455            | Lenalidomide          | 175                           | -                      |                                |
| 31 | 412            | Lenalidomide          | 216                           | Pembrolizumab           | 85                             |
|    |                |                       |                               |                        |                                |
| 32 | 302            | Ibrutinib             | 217                           | -                      |                                |
| 33 | 332            | Ibrutinib             | 220                           | -                      |                                |
|    |                |                       |                               |                        |                                |
| 34 | 270            | Ibrutinib             | 269                           | -                      |                                |
| 35 | 351            | Rituximab             | 297                           | -                      |                                |
| 36 | 547            | Rituximab             | 313                           | Transplant \(^b\)       | 87                             |
| 37 | 623            | Ibrutinib             | 366                           | Gemcitabine             | 132                            |
|    |                |                       |                               | oxaliplatin             |                                |
| 38 | 512            | Lenalidomide          | 395                           | Lenalidomide            | 98                             |
|    |                |                       |                               | obinutuzumab            |                                |
| 39 | 498            | Pembrolizumab         | 479                           | -                      |                                |

\(^a\)Intervals are shown as the days from the start date of one treatment to the start date of the next treatment.

\(^b\)Hematopoietic stem cell transplant.

Treatments started within 60 days were considered concurrent treatment; those started >60 days later were considered sequential treatment.